Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolonidine SCHEMBL11449439 | 0.88 | KMT2A (0.42) | RNASELALDH1A1MAPTGAALMNA | |
| SCHEMBL11372940 | 0.82 | HTT (0.33) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5157866 | 0.81 | ITGB3 (0.40) | MAPTGAAHSD17B10LMNAMEN1 | |
| SCHEMBL11370552 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTGAAHSD17B10LMNA | |
| SCHEMBL11448565 | 0.76 | CD44 (0.33) | — | |
| SCHEMBL10864418 | 0.76 | — | — | |
| Bromide SCHEMBL11460416 | 0.75 | CD44 (0.32) | — | |
| SCHEMBL10689485 | 0.75 | ALDH1A1 (0.46) | ALDH1A1MAPTHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL11370293 | 0.75 | AHR (0.33) | — | |
| SCHEMBL11356198 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | disclosed |
| EP-0081924-B1 | TOPICAL COMPOSTIONS FOR LOWERING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1986-02-19 | — | — | EP | disclosed |
| US-4517199-A | TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1985-05-14 | — | — | US | disclosed |
| US-4515800-A | GLAUCOMA | ALCON MANUFACTURING, LTD. | 1985-05-07 | — | — | US | disclosed |
| EP-0081924-A1 | Topical compostions for lowering intraocular pressure | ALCON LABORATORIES, INC. (US) | 1983-06-22 | — | — | EP | disclosed |
| EP-0035393-A1 | Poultry feeds containing and methods of using anovulatory compounds, and novel anovulatory imidazolines | MERCK & CO. INC. (US) | 1981-09-09 | — | — | EP | disclosed |
| US-4287201-A | CONTAINING A 2-(SUBSTITUTED PHENYLIMINO)IMIDAZOLIDINE COMPOUND | MERCK & CO., INC. (US) | 1981-09-01 | — | — | US | disclosed |
| US-4262005-A | CONTROLLING ECTOPARASITES WHICH ATTACK CATTLE AND PIGS | THE BOOTS COMPANY LIMITED (GB) | 1981-04-14 | — | — | US | disclosed |
| US-4213995-A | HYPOTENSIVE AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | RNASEL 3375/4885ALDH1A1 181/4885MAPT 2876/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | RNASEL 922/4885ALDH1A1 28/4885MAPT 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.